KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Common Equity (2017 - 2025)

Amneal Pharmaceuticals has reported Common Equity over the past 9 years, most recently at -$70.8 million for Q4 2025.

  • Quarterly results put Common Equity at -$70.8 million for Q4 2025, up 35.21% from a year ago — trailing twelve months through Dec 2025 was -$70.8 million (up 35.21% YoY), and the annual figure for FY2025 was -$70.8 million, up 35.21%.
  • Common Equity for Q4 2025 was -$70.8 million at Amneal Pharmaceuticals, up from -$110.0 million in the prior quarter.
  • Over the last five years, Common Equity for AMRX hit a ceiling of $407.4 million in Q1 2022 and a floor of -$132.0 million in Q1 2025.
  • Median Common Equity over the past 5 years was $142.7 million (2023), compared with a mean of $108.8 million.
  • Biggest five-year swings in Common Equity: tumbled 646.03% in 2024 and later surged 35.21% in 2025.
  • Amneal Pharmaceuticals' Common Equity stood at $367.0 million in 2021, then crashed by 49.87% to $184.0 million in 2022, then tumbled by 89.12% to $20.0 million in 2023, then tumbled by 646.03% to -$109.3 million in 2024, then skyrocketed by 35.21% to -$70.8 million in 2025.
  • The last three reported values for Common Equity were -$70.8 million (Q4 2025), -$110.0 million (Q3 2025), and -$112.5 million (Q2 2025) per Business Quant data.